How the timing of clot-removing treatment affects people with sudden pulmonary embolism
Looks at when clot-opening treatment is given in adults with acute pulmonary embolism.
Key facts
- Who runs it
- Azienda ULSS 8 Berica
- Where
- Italy7 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Optimal Time for Reperfusion in Acute Pulmonary Embolism
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 25 Nov 2025
- Planned end
- 30 Oct 2026
- Type of study
- Observational
- Record updated
- 3 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden blood clot in the lungs (acute pulmonary embolism) of high or intermediate-high risk. It is an observational study of how the timing of clot-removing treatment affects outcomes.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- High-risk or intermediate-high-risk pulmonary embolism, classified by the 2019 European Society of Cardiology guidelines. The diagnosis must be confirmed by CTPA (a CT scan of the lung arteries), pulmonary angiography, or echocardiography (heart ultrasound) showing a clot in the heart or main lung artery.
Main reasons for not taking part
- Younger than 18 years
- A high-risk or intermediate-high-risk pulmonary embolism was ruled out
- Unable to give informed consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥ 18 years
- Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery)
- Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines
- Provision of informed consent for the processing of personal data
Who cannot take part
- Age < 18 years
- Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded
- Inability to provide informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.
The group in the trial
- Patients with intermediate-high or high-risk pulmonary embolism
Patients with intermediate-high or high-risk pulmonary embolism stratified according to the ESC 2019 guidelines
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimal Time for Reperfusion in Acute Pulmonary Embolism
- Plain-language title
- How the timing of clot-removing treatment affects people with sudden pulmonary embolismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 3 March 2026